Brain metastases and testicular tumors: long-term survival.
In this updated and expanded retrospective analysis, the treatment records of 24 patients with brain metastases from nonseminomatous germ cell testicular tumors (NSGCT's) treated at the Indiana University Department of Radiation Oncology from 1975 through 1988 were reviewed. All patients received standard cisplatin-based induction chemotherapy. These patients were divided into three groups. Group 1 (n = 10) consisted of patients who presented initially with brain metastases and had no prior systemic treatment. Group 2 (n = 4) consisted of those patients who, after achieving a complete response (CR) with cisplatin, vinblastine, and bleomycin (PVB) +/- doxorubicin, developed a relapse confined to the brain. Group 3 (n = 10) consisted of those patients who were initially treated with PVB +/- doxorubicin or bleomycin, etoposide, and cisplatin (BEP) and eventually developed progressive disease and brain metastases. Group 1 was treated with whole brain irradiation (WBRT) and PVB +/- doxorubicin or BEP. Group 2 was treated with WBRT, cisplatin-based chemotherapy +/- surgical excision. Group 3 was usually treated with WBRT palliatively. Six patients, three in Group 1 and three in Group 2, are alive and disease-free with follow-up of 5+ years from beginning WBRT. Two additional patients in Group 1 survived 5+ years from beginning WBRT before dying with disease. No patient in Group 3 survived. Patients with brain metastases who have potentially controllable systemic disease should be treated curatively with WBRT (5000 cGy/25 fractions) +/- surgical excision and concomitant chemotherapy.
Spears
W T
WT
Department of Radiation Oncology, Indiana University Medical Center, Indianapolis 46202-5289.
Morphis
J G
JG
Lester
S G
SG
Williams
S D
SD
Einhorn
L H
LH
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001761:Bleomycin / Q000008:administration & dosage; D001932:Brain Neoplasms / Q000401:mortality* / Q000556:secondary* / Q000628:therapy; D002822:Choriocarcinoma / Q000401:mortality / Q000556:secondary / Q000628:therapy; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D005047:Etoposide / Q000008:administration & dosage; D006801:Humans; D008297:Male; D008649:Mesonephroma / Q000401:mortality / Q000556:secondary / Q000628:therapy; D009373:Neoplasms, Germ Cell and Embryonal / Q000401:mortality* / Q000556:secondary* / Q000628:therapy; D011879:Radiotherapy Dosage; D012189:Retrospective Studies; D013724:Teratoma / Q000401:mortality / Q000556:secondary / Q000628:therapy; D013736:Testicular Neoplasms / Q000401:mortality* / Q000628:therapy
D001761:Bleomycin; D005047:Etoposide; D002945:Cisplatin